|Bid price||134.50||Open price||135.50|
|Ask price||134.80||Prev close||134.80|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||FTSE 250|
|Latest Share Price (p)||134.80||Net Gearing (%)||-17.92|
|Market Capitalisation (£m)||915.26||Gross Gearing (%)||17.01|
|Shares in issue (m)||677.47||Debt Ratio||8.28|
|P/E Ratio||112.58||Debt-to-Equity Ratio||0.44|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.21|
|Dividend Yield (%)||0.00||Price to book value||3.86|
|Dividend cover (x)||0.00||ROCE (%)||-0.73|
|Earning per share (p)||1.20||EPS Growth (%)||33.33|
|52 week high / low||200.00 / 122.80||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|28/09/2016||EXR||Dr Trevor Phillips||ED||510,952|
|28/09/2016||SEXR||Dr Trevor Phillips||ED||240,841|
RNS Number : 9863M Vectura Group plc 19 October 2016 Vectura Group plc BLOCK LISTING RETURN Date: 19 October 2016 Name of applicant: Vectura Group plc Block Listing Return for the period 1 April 2016 to 30 September 2016 Name of scheme (s)...
RNS Number : 2823M Vectura Group plc 12 October 2016 Vectura Group plc Notice of Interim Results Chippenham, UK, 12 October 2016: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways disease focused business, plans to announce its...
Susan Foden, Non Executive Director, bought 6,500 shares in the company on the 30th September 2016 at a price of 139.60p. The Director now holds 17,500 shares representing 0.00% of the shares in issue. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com
Register now for FREE Vectura Group company news